Adam J Schoenfeld
Overview
Explore the profile of Adam J Schoenfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1744
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smithy J, Schoenfeld A, Betof Warner A
Transplant Cell Ther
. 2025 Mar;
31(3S):S626-S634.
PMID: 40089331
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating...
2.
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 40021433
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-line...
3.
Avutu V, Algazaq J, Seier K, Desir-Camille R, Qin L, Babatunde O, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39993596
Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are...
4.
Jeng M, Schoenfeld A
Clin Cancer Res
. 2025 Feb;
PMID: 39932719
Defining patterns of acquired resistance has important prognostic and therapeutic implications in patients with lung cancer. Longitudinal biomarker analysis has enhanced our understanding of tumor biology and treatment response. However,...
5.
Gandhi M, Elkrief A, Moore C, Ricciuti B, Alessi J, Richards A, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864548
Introduction: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in NSCLC, particularly among KRAS-mutant cases. Nevertheless, the frequency, clinicopathologic features, and clinical impact of...
6.
Cooper A, Arfe A, Ricciuti B, Gagne A, Sholl L, Di Federico A, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100759.
PMID: 39802817
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical,...
7.
Zucker M, Perry M, Gould S, Elkrief A, Safonov A, Thummalapalli R, et al.
Cell
. 2024 Dec;
188(3):851-867.e17.
PMID: 39701102
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients,...
8.
Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer
McMillan M, Shepherd A, Cooper A, Schoenfeld A, Wu A, Simone 2nd C, et al.
Radiother Oncol
. 2024 Dec;
203():110658.
PMID: 39626792
Background/purpose: The circadian clock governs the expression of genes related to immunity and DNA repair. We investigated whether the time of day of radiotherapy and/or systemic therapy infusions (chemotherapy or...
9.
Gormally M, Chen M, Noronha A, Panageas K, Reynolds M, Kohlasch K, et al.
JAMA Oncol
. 2024 Nov;
11(1):74-76.
PMID: 39602136
No abstract available.
10.
Altan M, Lopes G, Hiltermann T, Govindan R, Villaruz L, Calvo E, et al.
Clin Cancer Res
. 2024 Nov;
31(3):529-542.
PMID: 39576208
Purpose: The study aims to evaluate the safety, tolerability, and antitumor response of letetresgene autoleucel (lete-cel), genetically modified autologous T cells expressing a T-cell receptor specific for New York esophageal...